Protease-Activated Receptor-1, PAR-1 Agonist
|
P646344-10mg
|
≥98% |
141136-85-8 |
10mg
|
¥ 1900.9
|
期货,请咨询 |
阿拉丁 |
Peretinoin
|
P646343-5mg
|
≥98% |
81485-25-8 |
5mg
|
¥ 1000.9
|
期货,请咨询 |
阿拉丁 |
Peretinoin
|
P646343-50mg
|
≥98% |
81485-25-8 |
50mg
|
¥ 5120.9
|
期货,请咨询 |
阿拉丁 |
Peretinoin
|
P646343-2mg
|
≥98% |
81485-25-8 |
2mg
|
¥ 660.9
|
期货,请咨询 |
阿拉丁 |
Peretinoin
|
P646343-10mg
|
≥98% |
81485-25-8 |
10mg
|
¥ 1600.9
|
期货,请咨询 |
阿拉丁 |
Peretinoin
|
P646343-100mg
|
≥98% |
81485-25-8 |
100mg
|
¥ 8200.9
|
期货,请咨询 |
阿拉丁 |
PPAR agonist 1
|
P646339-1mg
|
|
539813-69-9 |
1mg
|
¥ 8900.9
|
期货,请咨询 |
阿拉丁 |
PROTAC HSP90 degrader BP3
|
P646332-5mg
|
≥98% |
2669072-88-0 |
5mg
|
¥ 6500.9
|
期货,请咨询 |
阿拉丁 |
PROTAC HSP90 degrader BP3
|
P646332-10mg
|
≥98% |
2669072-88-0 |
10mg
|
¥ 10200.9
|
期货,请咨询 |
阿拉丁 |
PHD-1-IN-1
|
P646307-5mg
|
≥99% |
2009343-14-8 |
5mg
|
¥ 2260.9
|
期货,请咨询 |
阿拉丁 |
PHD-1-IN-1
|
P646307-50mg
|
≥99% |
2009343-14-8 |
50mg
|
¥ 11560.9
|
期货,请咨询 |
阿拉丁 |
PHD-1-IN-1
|
P646307-25mg
|
≥99% |
2009343-14-8 |
25mg
|
¥ 7220.9
|
期货,请咨询 |
阿拉丁 |
PHD-1-IN-1
|
P646307-10mg
|
≥99% |
2009343-14-8 |
10mg
|
¥ 3610.9
|
期货,请咨询 |
阿拉丁 |
Py-BODIPY-NHS ester
|
P646237-5mg
|
≥98% |
201998-61-0 |
5mg
|
¥ 4800.9
|
期货,请咨询 |
阿拉丁 |
Py-BODIPY-NHS ester
|
P646237-10mg
|
≥98% |
201998-61-0 |
10mg
|
¥ 7800.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-Pyrotinib
|
P646232-5mg
|
≥98% |
1246089-97-3 |
5mg
|
¥ 6500.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-Pyrotinib
|
P646232-50mg
|
≥98% |
1246089-97-3 |
50mg
|
¥ 29500.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-Pyrotinib
|
P646232-25mg
|
≥98% |
1246089-97-3 |
25mg
|
¥ 19500.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-Pyrotinib
|
P646232-1mg
|
≥98% |
1246089-97-3 |
1mg
|
¥ 1900.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-Pyrotinib
|
P646232-10mg
|
≥98% |
1246089-97-3 |
10mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
P053
|
P646221-5mg
|
≥97% |
2748196-63-4 |
5mg
|
¥ 5000.9
|
期货,请咨询 |
阿拉丁 |
P053
|
P646221-50mg
|
≥97% |
2748196-63-4 |
50mg
|
¥ 30000.9
|
期货,请咨询 |
阿拉丁 |
P053
|
P646221-25mg
|
≥97% |
2748196-63-4 |
25mg
|
¥ 18000.9
|
期货,请咨询 |
阿拉丁 |
P053
|
P646221-10mg
|
≥97% |
2748196-63-4 |
10mg
|
¥ 8500.9
|
期货,请咨询 |
阿拉丁 |